Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAptamer Group Regulatory News (APTA)

Share Price Information for Aptamer Group (APTA)

Share Price is delayed by 15 minutes
Get Live Data
0.525    -0.025 (-4.55%)
Bid:
0.50
Ask:
0.55
Spread: 0.05 (10.00%)
Market Cap: £18.14m
APTA Live PriceLast checked at - London Stock Exchange

Intraday Aptamer Group Share Chart

Form 8.5 (EPT/RI)

31 Jul 2023 09:04

RNS Number : 7196H
Liberum Capital Limited
31 July 2023
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Liberum Capital Limited

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Aptamer Group Plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Aptamer Group Plc

(d) Date dealing undertaken:

28th July 2023

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

No

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

 

 

ORD 0.1p

 

 

Purchase

 

 

9,779

 

 

 

 

0.042

 

 

0.042

 

 

ORD 0.1p

 

 

 

Sale

 

 

 

 

10,000

 

 

0.04575

 

 

0.04575

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

Date of disclosure:

 31st July 2023

Contact name:

Shivani Ghiraiya

Telephone number:

020 3100 2213

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. 

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FERGIGDRXGXDGXB
Date   Source Headline
13th Apr 20261:08 pmRNSResult of General Meeting
31st Mar 20267:00 amRNSResult of Retail Offer and Posting of Notice of GM
26th Mar 20267:05 amRNSRetail Offer to raise up to £0.5 million
26th Mar 20267:00 amRNSResults of Placing
25th Mar 20267:10 amRNSInterim Results and Notice of Investor Webinar
25th Mar 20267:00 amRNSProposed Placing, Subscription and Retail Offer
18th Mar 20267:00 amRNSLaunch of targeted radiopharmaceutical programme
10th Mar 20263:26 pmRNSBlock Listing Interim Review
17th Feb 20267:00 amRNS-RTechnical Feasibility for Pathogen Detector
11th Feb 20267:00 amRNSOptimer® Technology in Launched Library Prep Kit
29th Jan 20267:00 amRNSContract wins and first cash licensing receipts
7th Jan 20264:04 pmRNSTrading update - Media comment and speculation
7th Jan 20267:00 amRNSHalf Year Trading Update
23rd Dec 20257:00 amRNSAptamer signs licensing agreement with Alphazyme
23rd Dec 20257:00 amRNSAptamer signs licensing agreement with Alphazyme
16th Dec 202510:34 amRNSLicensing agreement with Twist Bioscience
27th Nov 20251:01 pmRNSResults of 2025 Annual General Meeting
27th Nov 20257:00 amRNSAGM Statement
14th Nov 20257:00 amRNSStrong contract wins build commercial momentum
4th Nov 20257:00 amRNSNew contract with top five pharma company
3rd Nov 20257:00 amRNSPosting of Annual Report and Notice of AGM
14th Oct 20257:00 amRNSFull Year Results for the 12mths to 30 June 2025
13th Oct 20257:00 amRNSNew contract with top 10 pharma
10th Oct 20257:00 amRNSNotice of Results, Analyst & Investor Presentation
8th Oct 20257:00 amRNSMajor top 3 global pharma contract win
26th Sep 20257:00 amRNS-RInvestor Event and Presentation
11th Sep 20257:00 amRNS-RNew contract with Metir plc
9th Sep 20257:00 amRNSNotification of dealings by a director/PDMR
2nd Sep 20257:00 amRNSTherapeutic development agreement with Invizius
28th Aug 20257:00 amRNSBlock Listing Interim Review
27th Aug 20257:00 amRNSBiomarker Discovery Service Launch
22nd Aug 20257:00 amRNSUpdate on licensing and development progress
19th Aug 20257:00 amRNSExercise of warrants
18th Aug 20253:44 pmRNSHolding(s) in Company
18th Aug 20257:00 amRNSContract extension with global pharma partner
8th Aug 20257:00 amRNS-RInvestor Technical Webinar
7th Aug 20255:24 pmRNSHolding(s) in Company
5th Aug 20258:05 amRNSHolding(s) in Company
31st Jul 20251:29 pmRNS-RInvestor Webinar
31st Jul 20257:00 amRNSTrading Update
28th Jul 202512:25 pmRNSHolding(s) in Company
24th Jul 202511:48 amRNSResult of General Meeting
21st Jul 20257:00 amRNSAdditional work commissioned by Unilever
18th Jul 20257:00 amRNSIssue of Equity in lieu of Non-Exec Director Fees
9th Jul 20252:53 pmRNSHolding(s) in Company
8th Jul 20257:00 amRNSPosting of Circular and Notice of General Meeting
4th Jul 20257:00 amRNSPlacing to raise £2.0 million
30th Jun 20257:00 amRNSLiver fibrosis breakthrough with Optimer® platform
25th Jun 20257:00 amRNSAgreement with global life sciences leader
30th May 20257:00 amRNSUnilever second Optimer development programme

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.